The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.

FIELD OF THE INVENTION

Topical corticosteroids are useful for their anti-inflammatory, anti-pruritic and vasoconstrictive actions. Corticosteroids (or corticoids) are any steroids (lipids that contain a hydrogenated cyclopentoperhydrophenanthrene ring system) elaborated by the adrenal cortex (except sex hormones of adrenal origin) in response to the release of adrenocorticotrophin or adrenocorticotropic hormone by the pituitary gland, or to any synthetic equivalent, or to angiotensin II. Corticosteroids include but are not limited to alclometasone dipropionate, amcinonide, amcinafel, amcinafide, beclamethasone, betamethasone, betamethasone dipropionate, betamethasone valerate, clobetasone propionate, chloroprednisone, clocortelone, cortisol, cortisone, cortodoxone, difluorosone diacetate, descinolone, desonide, defluprednate, dihydroxycortisone, desoximetasone, dexamethasone, deflazacort, diflorasone diacetate, dichlorisone, esters of betamethasone, flucetonide, flucloronide, fluorocortisone, flumethasone, flunisolide, fluocinonide, fluocinolone acetonide, flucortolone, fluperolone, fluprednisolone, fluroandrenolone acetonide, fluocinolone acetonide, flurandrenolide, fluorametholone, fluticasone propionate, hydrocortisone, hydrocortisone butyrate, hydrocortisone valerate, hydrocortamate, medrysone, meprednisone, methylprednisone, methylprednisolone, mometasone furoate, paramethasone, prednisone, prednisolone, prednidone, triamcinolone acetonide, and triamcinolone.

Hydrocortisone was the first corticosteroid found to be topically effective. Other more potent glueoeorticoids, which are a subset of corticosteroids that affect carbohydrate metabolism, inhibit corticotropin secretion, and possess pronounced anti-inflammatory activity, have since been developed. Currently, topical steroids are among the most frequently prescribed of all dermatological drug products.

It is believed that glucocorticoids exert their potent anti-inflammatory effects by inhibiting the formation of prostaglandins and other derivatives of the arachidonic acid pathway. It is known that glucocorticoids inhibit the release of phospholipase A2, the enzyme responsible for liberating arachidonic acid from cell membranes, thus inhibiting the arachidonic acid pathway. Currently, it is believed that glucocorticoids inhibit phospholipase A2, in cells by directly inducing phosphorylation of the enzyme.

Steroids are commonly divided into two classes, fluorinated and nonfluorinated. Fluorinated steroids have been chemically modified to increase potency. These modifications, such as halogenation and methylation, can result in improved activity within the target cell and in decreased breakdown to inactive metabolites. These modifications can also lead to more systemic side effects. However, modification of the chemical structure of the steroid is not the only way to increase potency.

The potency of topical steroid preparations is strongly correlated to their absorption through the skin. Treatment of the skin prior to application of the topical steroid may also affect the absorption of the compounds into the skin. Treatments with keratolytics or with fat solvents (such as acetone) disrupt the epidermal barrier and increase penetration. Hydrating the skin has also been shown to increase the penetration of the corticosteroids.

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. The potencies of corticosteroids vary greatly and it is a challenge to increase the potency of any particular steroid.

BACKGROUND OF THE INVENTION

The clinical effectiveness of corticoids is related to four basic properties: vasoconstriction, antiproliferative effects, immunosuppression, and anti-inflammatory effects. Topical steroids cause the capillaries in the superficial dermis to constrict, thus reducing erythema. The ability of a given glucocorticoid agent to cause vasoconstriction usually correlates with its anti-inflammatory potency. Vasoconstrictor assays are used in the art and by the U.S. Food and Drug Administration for determining the potency of topical corticosteroid preparations. Topical glucocorticoid preparations have been divided in the field into seven classes based on potency based on double-blind clinical studies and vasoconstrictor assays. Class 1 includes the most potent, while class 7 contains the least potent.

The following glucocorticoid preparations were designated in Fitzpatrick, Dermatology in General Medicine, 5.sup.th edition, CD-ROM, 1999, Table 243-1, with the following classes.

TABLE-US-00001 TABLE 1 Corticosteroid Preparation Corticosteroid Class Source Temovate .RTM. Clobetasone 1 Glaxo Wellcome Cream 0.05% propionate Temovate .RTM. Clobetasone 1 Glaxo Wellcome ointment 0.05% propionate Diprolene .RTM. Betamethasone 1 Schering Corp. cream 0.05% dipropionate Diprolene .RTM. Betamethasone 1 Schering Corp. ointment 0.05% dipropionate Psorcon .RTM. Diflorasone 1 Dermik Laboratories, ointment diacetate Inc. Cyclocort .RTM. Amcinonide 2 Fujisawa ointment 0.1% Diprolene .RTM. Betamethasone 2 Schering Corp. cream AF dipropionate 0.05% Diprosone .RTM. Betamethasone 2 Schering Corp. ointment 0.05% dipropionate Elocon .RTM. Mometasone 2 Schering Corp. ointment 0.1% furoate Florone .RTM. Diflorasone 2 Dermik ointment 0.05% diacetate Halog .RTM. cream Halcinonide 2 Westwood-Squibb 0.1% Lidex .RTM. gel Fluocinonide 2 Medicis Pharmaceuticals 0.05% Corp. Lidex .RTM. cream Fluocinonide 2 Medicis Pharmaceuticals 0.05% Corp. Lidex .RTM. Fluocinonide 2 Medicis Pharmaceuticals ointment 0.05% Corp. Maxiflor .RTM. Diflorasone 2 Allergan Herbert ointment 0.05% diacetate Topicort .RTM. Desoximetasone 2 Medicis Pharmaceuticals cream 0.25% Corp. Topicort .RTM. gel Desoximetasone 2 Medicis Pharmaceuticals 0.05% Corp. Topicort .RTM. Desoximetasone 2 Medicis Pharmaceuticals ointment 0.25% Corp. Aristocort A .RTM. Triamcinolone 3 Fujisawa ointment 0.1% acetonide Cutivate .RTM. Fluticasone 3 Glaxo Wellcome ointment propionate 0.005% Cyclocort .RTM. Amcinonide 3 Fujisawa cream 0.1% Cyclocort .RTM. Amcinonide 3 Fujisawa Lotion 0.1% Diprosone .RTM. Betamethasone 3 Schering Corp. cream 0.05% dipropionate Florone .RTM. cream Diflorasone 3 Dermik 0.05% diacetate Halog .RTM. Halcinonide 3 Westwood-Squibb ointment 0.1% Lidex .RTM. E Fluocinonide 3 Medicis Pharmaceutical cream 0.05% Corp. Maxiflor .RTM. Diflorasone 3 Allergan Herbert cream 0.05% diacetate Valisone .RTM. Betamethasone 3 Schering Corp. ointment 0.1% valerate Cordran .RTM. Flurandrenolide 4 Oclassen ointment 0.05% Elocon .RTM. cream Mometasone 4 Schering Corp. 0.1% furoate Kenalog .RTM. Triameinolone 4 Westwood-Squibb cream 0.1% acetonide Synalar .RTM. Fluocinolone 4 Medicis Pharmaceuticals ointment acetonide Corp. 0.025% Westcort .RTM. Hydrocortisone 4 Westwood-Squibb ointment 0.2% valerate Cordran .RTM. Flurandrenolide 5 Oclassen cream 0.05% Cutivate .RTM. Fluticasone 5 Glaxo Wellcome cream 0.05% propionate Diprosone .RTM. Betamethasone 5 Schering Corp. lotion 0.05% dipropionate Kenalog .RTM. Triamcinolone 5 Westwood-Squibb lotion 0.1% acetonide Locoid .RTM. cream Hydrocortisone 5 Ferndale 0.1% butyrate Synalar .RTM. cream Flucinolone 5 Medicis Pharmaceuticals 0.025% acetonide Corp. Valisone .RTM. Betamethasone 5 Schering Corp. cream 0.1% valerate Westcort .RTM. Hydrocortisone 5 Westwood-Squibb cream 0.2% valerate Aclovate .RTM. Alclometasone 6 Glaxo Wellcome cream 0.05% dipropionate Aclovate .RTM. Alclometasone 6 Glaxo Wellcome ointment 0.05% dipropionate Aristocort .RTM. Triamcinolone 6 Fujisawa cream 0.1% acetonide Desowen .RTM. Desonide 6 Galderma cream 0.05% Synalar .RTM. Fluocinolone 6 Medicis Pharmaceuticals solution 0.01% acetonide Corp. Synalar .RTM. cream Fluocinolone 6 Medicis Pharmaceuticals 0.01% acetonide Corp. Tridesilon .RTM. Desonide 6 Miles cream 0.05% Valisone .RTM. Betamethasone 6 Schering Corp. lotion 0.1% valerate Topicals with 7 hydrocortisone dexamethasone, flumethasone, prednisolone, and methylprednisolone

All percentages given are weight percentages unless otherwise noted.

Although there is no significant difference between potencies within Class 2, within Class 1 Temovate.RTM. cream or ointment is significantly more potent than Class 1 Diprolone.RTM. cream or ointment of Schering and Class 1 Psorcon.RTM. ointment of Dermik Laboratories, Inc.

Several factors such as the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings affect the percutaneous absorption and resulting potency of corticosteroids regardless of the intrinsic potency of the glucocorticosteroid (or glucocorticoid) molecule. Further, inflammation and/or other disease processes in the skin increase percutaneous absorption.

The vehicle in which the corticoid is incorporated may be as important as the corticoid molecule itself in determining the potency of a given formulation because the vehicle affects the amount of corticoid that is released in any given period of time, and its absorption. In many corticosteroid compositions, the vehicle is as much as 99% of the total composition. Very occlusive vehicles, such as ointments (water-insoluble mixtures of oil and petrolatum), increase the corticosteroid effect because they provide increased hydration of the stratum corneum and increase the skin's permeability. By covering the skin with an occlusive dressing such as plastic wrap, this effect can be heightened as much as 100-fold. The solubility of the corticoid in the vehicle also affects penetration into the skin.

Creams, which are suspensions of oil in water, have also been used as vehicles for corticosteroids. The compositions of creams vary and are far less greasy than ointments but do not provide the same degree of hydration to the skin, and therefore may not have as high penetration as ointments. Lotions, which are suspensions of oil in water and are similar to creams, are vehicles which include agents to help solubilize the corticosteroids. Solutions have been used as vehicles and are water based with propylene glycol. Gels are solid components at room temperature but melt on the skin. Lotions, gels and solutions have less penetration than ointments.

Many vehicles for corticosteroids include propylene glycol for dissolving the corticosteroid in the vehicle. In general, compositions that contain higher amounts of propylene glycol tend to be more potent.

Vehicles are so important in the potency of corticosteroids that different formulations containing the same amount of the same corticosteroid often are in different potency classes. For example, commercially available preparations of 0.05% betamethasone dipropionate are classified as having Class 1, Class 2 or Class 3 potency, depending on their vehicles (as seen in Table 1 -- see Original Patent).

SUMMARY OF THE INVENTION

The present invention comprises a novel vehicle which is safe for topical application, stable, and provides increased potency for corticosteroid preparations, especially fluorinated corticosteroids.

An embodiment of the present invention delivers the corticosteroid in a vehicle that comprises a corticosteroid, and (a) at least two penetration enhancers, including propylene glycol, dimethyl isosorbide or diusopropyl adipate, (b) solvents and/or emulsifiers for the corticosteroid and optionally the penetration enhancers and (c) optionally, non-solvent/emulsifier ingredients. The vehicle has a ratio of a:(a+b) that is greater than or equal to 0.70, preferably greater than or equal to 0.80 and most preferably greater than or equal to 0.90 or 0.95.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention enhances the potency of corticosteroid preparations with a vehicle comprising at least two penetration enhancers, including diusopropyl adipate, dimethyl isosorbide, propylene glycol, 1,2,6-hexanetriol, and benzyl alcohol. The corticosteroids with which this invention may be used include, but are not limited to, fluorinated corticosteroids.

Another embodiment of the present invention is a method for enhancing the potency of corticosteroids, preferably fluorinated corticosteroids. The corticosteroid is combined with two or more penetration enhancers (preferably propylene glycol and at least one other penetration enhancer), and one or more solvents and emulsifiers for the corticosteroid and optionally penetration enhancers, wherein the penetration enhancers are present in ratio to the total of the penetration enhancers, and solvents and emulsifiers of at least about 0.70, preferably at least 0.80 and most preferably 0.90 or 0.95. Optionally, one or more inactive ingredients may also be combined with the corticosteroid.

Another embodiment of the present invention is a method of delivering corticosteroids to skin, nails or hair, preferably mammalian skin, most preferably human, dog or cat skin. The corticosteroids are preferably fluorinated corticosteroids. The corticosteroid is combined with two or more penetration enhancers, and one or more solvents and emulsifiers for the corticosteroid, wherein the penetration enhancers are present in ratio to the total of the penetration enhancers, and solvents and emulsifiers of at least about 0.70, preferably at least 0.85 and most preferably 0.90 or 0.95. Optionally, one or more inactive ingredients may also be combined with the corticosteroid.

As indicated above, this invention is broadly applicable to corticosteroids in general, and fluorinated corticosteroids in particular, most preferably fluocinonide or fluocinolone acetonide. The following examples show its application to preparations of fluocinonide, a commonly used fluorinated corticosteroid. Fluocinonide is a corticosteroid which is the 21-acetate ester of fluocinolone acetonide with the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-,(6.alpha.,11.beta., 16.alpha.)-.

Compositions containing 0.05% (all percentages are weight percentages) fluocinonide are commonly classified as Class 2.
 

Claim 1 of 15 Claims

1. A method of delivering corticosteroids to skin comprising: Topically applying a composition comprising one or more corticosteroids with two or more penetration enhancers, and one or more of the group consisting of solvents and emulsifiers, wherein the penetration enhancers are present in ratio to a total of the penetration enhancers, and solvents and emulsifiers of at least about 0.90, and wherein the penetration enhancers comprise two or more of the group consisting of propylene glycol, diisopropyl adipate, dimethyl isosorbide, 1,2,6 hexanetriol, and benzyl alcohol.
 

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.